Loading clinical trials...
Loading clinical trials...
A Phase II Study of Combination Rituximab-CHOP and Bortezomib (Velcade®) (R-CHOP-V) Induction Therapy Followed by Bortezomib Maintenance (VM) Therapy for Patients With Newly Diagnosed Mantle Cell Lymphoma
Conditions
Interventions
rituximab
bortezomib
+4 more
Locations
147
United States
Alaska Regional Hospital Cancer Center
Anchorage, Alaska, United States
Providence Cancer Center
Anchorage, Alaska, United States
Arizona Cancer Center at University of Arizona Health Sciences Center
Tucson, Arizona, United States
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Providence Saint Joseph Medical Center - Burbank
Burbank, California, United States
North Bay Cancer Center
Fairfield, California, United States
Start Date
August 1, 2006
Primary Completion Date
December 1, 2012
Completion Date
September 1, 2017
Last Updated
November 6, 2017
NCT04570423
NCT07249528
NCT00131014
NCT03050268
NCT07545603
NCT07137494
Lead Sponsor
SWOG Cancer Research Network
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions